MD Anderson and Virogin Biotech form collaboration to accelerate oncolytic virus R&D

UCSD’s Comprehensive Cancer Center designation is in trouble; director Califano steps down amid turmoil

The Moores Cancer Center at UC San Diego Health is in imminent danger of losing its Comprehensive designation, and members of the center’s External Advisory Board are urging the leadership of the parent institution to act fast.

Drug shortages threaten lives—cancer patients cannot wait

The shortage of certain cancer drugs is a serious and life-threatening issue for cancer patients across the United States. This, however, is not a new issue. Drug shortages are a cyclical event, and we need a durable solution to ensure that cancer patients have access to the drugs and the treatment they need to survive.

Sexual harassers should face consequences: As NIH director, Bertagnolli can foster change

Last year, the NIH announced that at the direction of Congress, the organization would tighten rules for reporting sexual and workplace harassment by investigators funded by the NIH.

June 02, 2023

Vol.49 No.22

By Shikha Jain

Clinical

ComboMATCH trial—a collaboration across NCI and NCTN groups—matches patients with combination therapy trials based on tumor biology

NCI and all five cooperative groups that make up the National Clinical Trials Network have launched a large-scale precision medicine initiative that will match cancer patients with early-phase clinical trials testing novel drug combinations that target specific tumor alterations.

Marcus Humphrey on the long road to diagnosis and successful treatment of lymphoma with CAR T-cell therapy

In January 2021 Mary Humphrey made several phone calls to find an oncologist who would treat her husband, Marcus Humphrey, for a lump that had grown rapidly and exponentially on the right side of his neck.

June 02, 2023

Vol.49 No.22

In Brief

Ezra Cohen named chief medical officer of oncology at Tempus

Ezra Cohen was named chief medical officer of oncology at Tempus, an artificial intelligence and precision medicine company.

June 02, 2023

Vol.49 No.22

MD Anderson and Virogin Biotech form collaboration to accelerate oncolytic virus R&D

YOU MAY BE INTERESTED IN

UCSD’s Comprehensive Cancer Center designation is in trouble; director Califano steps down amid turmoil

Drug shortages threaten lives—cancer patients cannot wait

Sexual harassers should face consequences: As NIH director, Bertagnolli can foster change

ComboMATCH trial—a collaboration across NCI and NCTN groups—matches patients with combination therapy trials based on tumor biology

Marcus Humphrey on the long road to diagnosis and successful treatment of lymphoma with CAR T-cell therapy

Ezra Cohen named chief medical officer of oncology at Tempus

Renew today!

Subscriber content

Login